Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing Value Of Abuse-Deterrent Labeling Weighed At Vantrela Review

Executive Summary

Advisory committee members concerned about 'unintended consequences' of labeling opioid products as having deterrent effects want FDA to closely monitor promotion.

Advertisement

Related Content

Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says
When Is An Abuse-Deterrent Claim FDA Approved?
When Is An Abuse-Deterrent Claim FDA Approved?
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel